ruxolitinib
ruxolitinib: developed by 1 company · 126 clinical trials tracked · 2 FDA decisions.
ruxolitinib evidence translation
What we can confirm
2 FDA records · 126 tracked trials
What it means
What to watch
Prepared research question
How could ruxolitinib → INCY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 9 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Incyte Corp. (INCY) | Approved |
Clinical Trials (126)showing 10 most recent
Ruxolitinib for Chuvash Polycythemia
Phase Ib/II Study Of Revumenib As Monotherapy Or In Combination With Jak Inhibitors In Patients With Myelofibrosis
Primary endpoint: Dose limiting toxicity (DLT)
A Phase 2/3, Randomized, Open-label, Active-comparator-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543) Versus Best Available Therapy in Participants With Polycythemia Vera Who Have an Inadequate Response to or Are Intolerant to Hydroxyurea
Primary endpoint: Clinicohematologic Response (CHR) Rate
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
Primary endpoint: Number of Participants with Clinical Response
A Phase 2 Study of Belumosudil Combined With Ruxolitinib as Second Line Therapy to Treat Chronic Graft Versus Host Disease (cGvHD) After Steroid Failure (BELRUX)
Primary endpoint: Efficacy will be assessed using overall response rate (ORR) as per the NIH cGvHD Consensus Response Criteria at 24 weeks of combination treatment. Tolerability and safety will be assessed by the incidence and severity of adverse events (AEs)
A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive
Primary endpoint: Number of Participants with Splenic Response (SVR35) by Central Radiology Reads at Week 24 in participants with baseline total symptom score (TSS) ≥ 25
Ruxolitinib-Enhanced Conditioning for Pediatric and Young Adult Patients With Symptomatic Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation
Primary endpoint: Event Free Survival
An Open Label, Non-Randomized, Multi-Center Pilot Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for GVHD Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Primary endpoint: Severe acute GVHD-free Survival (SGFS)
Study of JAK Inhibition in Stem-Like Prostate Cancer (JASPER): A Phase 1b/2a Multicenter Study of Ruxolitinib and Enzalutamide in Castration Resistant Prostate Cancer
Primary endpoint: Dose-limiting toxicity (DLT)
An Open-Label, Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants
Primary endpoint: Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib
FDA Decisions2 records
Frequently asked questions
Who is developing ruxolitinib?
ruxolitinib is being developed by Incyte Corp..
How many clinical trials involve ruxolitinib?
BioSniper tracks 126 clinical trials involving ruxolitinib.
What is ruxolitinib's latest FDA decision?
The most recent tracked FDA decision for ruxolitinib is Approval for 1 INDICATIONS AND USAGE OPZELURA is a Janus kinase (JAK) inhibitor indicated for: the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ( 1.1 ) the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. ( 1.2, dated September 21, 2021.